What's new in WHODrug

The WHODrug portfolio is continually being updated and further developed. This includes new and revised SDGs, updates following the annual ATC revision, and developments in the WHODrug toolbox, such as a new automated service for verification of the WHODrug licenses of collaborating partners. Read more in the document 'What's New in WHODrug March 1, 2019' available for download at the UMC website.

To hear more WHODrug news, you have the opportunity to join us for a webinar entitled 'What's New in WHODrug' on Tuesday, March 5, 2019. WHODrug users can sign up for the webinar here.

WHODrug only available in B3 and C3 formats from March 1, 2019 release

Since March 1st, 2017, the UMC has distributed the B2/C formats in parallel with the B3/C3 formats to facilitate smoother implementation for WHODrug users. This transition period comes to an end on March 1st, 2019, when the B3 format will finally replace the B2, and the C3 format will replace the C. To learn more about implementing the WHODrug B3/C3 formats, regulatory expectations of using the new formats, and more, please visit the dedicated B3/C3 format section on the UMC website.

WHODrug Koda launch approaching, plus improved trial version

WHODrug Koda is an automated drug coding engine custom-built by UMC that can automatically code a drug name to the corresponding record in WHODrug Global, and select the most appropriate ATC code. By employing a unique combination of Artificial Intelligence by machine-learning, thorough and continual training of the engine, together with UMC’s unrivalled WHODrug expertise, WHODrug Koda increases drug coding consistency and efficiency at the same time as it reduces coding bias.

WHODrug Koda will be officially released for purchase from mid-March 2019. The full version of WHODrug Koda features improved ATC selection functionality and upgraded logic to code or suggest drug names. Join us in celebrating the launch of WHODrug Koda by attending our dedicated upcoming webinar. WHODrug users can sign up for it here.

WHODrug Koda will remain available to all WHODrug users as a trial web-application for a limited number of 200 terms per organisation. The trial application will also be updated to reflect the enhanced features available in the official version of WHODrug Koda.

Discontinuation of WHODrug Enhanced

With WHODrug Global now available to all WHODrug users, and to further standardise the WHODrug portfolio, the sunset of WHODrug Enhanced is only 18 months away. WHODrug Enhanced will continue to be produced in parallel with WHODrug Global until September 2020, when it will finally be discontinued.

Forthcoming User Group Meetings

Join us for any of our 2019 WHODrug User Group Meetings to learn more about WHODrug, participate in interactive workshops, and network with colleagues in the industry. Below is a list of forthcoming meetings:

• Hyderabad, India, March 11, 2019.
• Prague, Czech Republic, April 9, 2019.
• Beijing, China, May 16, 2019. In association with this meeting, UMC are also offering a half-day WHODrug training session on May 15.
• San Diego, CA, USA, June 28, 2019.

More meetings will be announced in due course. Registration is free of charge if you are working for an organisation with a valid WHODrug license. For more information and to register, please visit the UMC website.

New versions of WHODrug documents available

For the March 2019 release, UMC has released new versions of the following documents:

• What’s New in WHODrug March 1, 2019
• WHODrug User Guide Version 4.0
• Standardised Drug Grouping (SDG) User Guide 2019
• WHODrug Version Verification March 1, 2019
• Cross Reference Tool Japan (CRT Japan) User Guide version 5.0, 2018
• Cross Reference Tool Japan (CRT Japan) 3 = メディカルデータ a 5, 2019
• Cross Reference ATC5 User Guide version 6.0, 2019

All WHODrug documentation is available to WHODrug users at the WHODrug library on the UMC website.

Questions?

For any questions, please contact us at WHODrug@who-umc.org.